AARON THRIFT to Liver Neoplasms
This is a "connection" page, showing publications AARON THRIFT has written about Liver Neoplasms.
Connection Strength
6.662
-
The Association Between Physical Activity, Sedentary Time, and Sleep with Risk of Hepatocellular Carcinoma in Patients with Cirrhosis. Dig Dis Sci. 2026 Apr; 71(4):1522-1529.
Score: 0.447
-
PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
Score: 0.403
-
Response to letter entitled: Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer. 2024 Jun; 204:114041.
Score: 0.400
-
Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
Score: 0.371
-
Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer. 2022 Sep; 173:250-262.
Score: 0.357
-
Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2023 08; 21(9):2418-2420.e3.
Score: 0.357
-
Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas. Clin Gastroenterol Hepatol. 2023 05; 21(5):1314-1322.e5.
Score: 0.356
-
Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1402-1409.
Score: 0.354
-
Modest Impact of Liver Transplantation on Hepatocellular Carcinoma Mortality in the United States, Findings from The Transplant Cancer Match (TCM) Study. Cancer Epidemiol Biomarkers Prev. 2021 03; 30(3):435-437.
Score: 0.323
-
Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021 Apr; 32(4):317-325.
Score: 0.320
-
Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
Score: 0.296
-
Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):88-94.
Score: 0.295
-
Authors' reply to: Statin use and risk of liver cancer. Int J Cancer. 2019 10 01; 145(7):2009.
Score: 0.287
-
Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. PLoS One. 2019; 14(4):e0214721.
Score: 0.283
-
Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019 09; 17(10):2117-2125.e3.
Score: 0.278
-
HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. J Hepatol. 2026 Mar; 84(3):578-586.
Score: 0.111
-
Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits. Int J Cancer. 2026 Mar 01; 158(5):1193-1203.
Score: 0.111
-
Neighborhood-level deprivation mediates racial and ethnic disparities in HCC diagnosis in Texas. Hepatol Commun. 2024 Nov 01; 8(11).
Score: 0.104
-
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
Score: 0.104
-
Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study. Environ Res. 2024 Jan 01; 240(Pt 2):117538.
Score: 0.097
-
Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
Score: 0.094
-
Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
Score: 0.094
-
Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
Score: 0.093
-
Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
Score: 0.090
-
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
Score: 0.078
-
Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.
Score: 0.078
-
Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
Score: 0.076
-
Statin use and risk of liver cancer: Evidence from two population-based studies. Int J Cancer. 2020 03 01; 146(5):1250-1260.
Score: 0.072
-
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
Score: 0.068
-
Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018 07; 48(1):55-64.
Score: 0.066
-
Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
Score: 0.061
-
Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
Score: 0.060
-
Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
Score: 0.059
-
Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
Score: 0.021